Skip To Main Content
William H Hind on Muck Rack

William H Hind

Manchester
As seen in: PLOS ONE, BMJ Open, Pharmaphorum, Life Science Leader, PM360, Healthcare Business Today, Cell & Gene
Expert in market development and medical communications in healthcare sector, focused on speciality products. Dad, rugby fan, sailor
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with William H

Contact William H, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Theory-based predictors of prescribing behaviour for neurodegenerative diseases: A cross-sectional survey with European healthcare professionals

|
By Emma Begley, Jason Thomas, William H Hind
| PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Citation: Begley E, Thomas JM, Hind W, Senior C (2026) Theory-based predictors of prescribing behaviour for neurodegenerative diseases: A cross-sectional survey with European healthcare professionals. PLoS One 21(7): e0353479. https://doi.org/10.1371/journal.pone.0353479 Editor: Abdallah Y.
Open in Who Shared Issue with article?

Can behavioural science be used to understand factors that influence the prescription choice for Parkinson’s disease? A pan-European focus group study of clinicians’ prescribing practice

|
By Emma Begley, Jason Thomas, William H Hind, Carl Senior
| BMJ Open Verified
Methodology This study is qualitative and draws on deductive and inductive analysis. Cross-sectional online focus groups were designed and delivered using the Nominal Group Technique (NGT) method to identify and establish a consensus on the factors that influence HCPs’ choice of medication for patients with PD.
Open in Who Shared Issue with article?

GUEST COMMENTARY: Patient-Focused Drug Development: Identifying Patient Priorities

|
By William H Hind, Lisa Campbell
| PM360 Verified
Unless patients have a voice right from product conception and design, new treatments could be poorly aligned with their needs, affecting take-up and commercial success. Unless patient considerations are central to the earliest stages of drug discovery and development—the premise of so-called Patient Focused Drug Development (PFDD)—new treatments or applications of a medicine could fail to make the grade.
Open in Who Shared Issue with article?
See all 8 articles